A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Aug 2019 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 13 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2020.
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.